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The intestinal milieu is astonishingly complex, 
home to a constantly changing cocktail of small and 
large molecules, along with an abundance of 
bacteria, viral particles, and eukaryotic cells. Such 
complexity makes it difficult to develop testable 
molecular hypotheses regarding host-microbe 
interactions. Fortunately, mammals and their 
associated gastrointestinal (GI) microbes contain 
complementary systems that are ideally suited for 
mechanistic studies. Mammalian systems inactivate 
endobiotic and xenobiotic compounds by linking 
them to a glucuronic acid sugar for GI excretion. In 
the GI tract, the microbiota express β-glucuronidase 
enzymes that remove the glucuronic acid as a 
carbon source, effectively reversing the actions of 
mammalian inactivation. Thus, by probing the 
actions of microbial β-glucuronidases, and by 
understanding which substrate glucuronides they 
process, molecular insights into mammalian-
microbial symbioses may be revealed amid the 
complexity of the intestinal tract. Here, we focus on 
glucuronides in the gut, and the microbial proteins 
that process them. 
 
β-glucuronidase (GUS) enzymes expressed 
by the GI microbiota are at the interface of a 
metabolic symbiosis between microbe and host 
where they mediate the reactivation of molecules 
important in host health and disease. Microbial 
GUS enzymes regenerate toxic drugs and 
carcinogens in the mammalian GI (1), and their 
activities are associated with higher incidence of 
colon cancer and to diets that promote intestinal 
cancer (2). Endogenous molecules are also 
processed by GI GUS proteins, including 
glucuronides of hormones and neurotransmitters 
(3–5). These observations have led to hypotheses 
linking microbial GUS enzymes to the GI toxicity 
of drugs, the development of cancer, and increased 
incidence of Crohn’s disease and colitis (2, 6–9). 
Thus, bacterial GUS enzymes appear to play an 
important role in health and disease by 
metabolizing glucuronides in the gut. 
GUS proteins catalyze the hydrolysis of 
glycosidic bonds between glucuronic acid and 
either small molecules or the terminal ends of 
polysaccharides. For the purposes of this review, 
we will focus on small molecule glucuronides 
generated by Phase II drug metabolism to mark 
compounds for excretion. Glucuronides are 
produced by mammalian uridine diphosphate 
(UDP)-glucuronosyl transferase (UGT) enzymes 
that append glucuronic acid, derived from UDP-
glucuronate, to hydroxyl, carboxylate, and other 
nucleophilic functional groups of aglycones (10). 
Glucuronidation almost exclusively inactivates and 
detoxifies molecules by increasing their water 
solubility, which promotes their removal from the 
body via the kidneys or GI tract (11). Once in the 
GI tract, these glucuronides serve as substrates for 
bacterial GUS proteins that remove the inactivating 
glucuronic acid moiety. Glucuronic acid then enters 
the Entner-Doudoroff pathway, a bacterial 
alternative to glycolysis that catabolizes sugar acids 
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and shunts the resulting pyruvate into the TCA 
cycle (12). Mammals also express a GUS enzyme 
ortholog that is localized to lysosomes in first-pass 
tissues like liver and intestines, and plays an 
essential role in degrading endogenous 
glycosaminoglycans (13). Germ-line mutations in 
human GUS cause Sly syndrome, a fatal lysosomal 
storage disease (14). Human GUS has also been 
shown to hydrolyze small-molecule glucuronides, a 
function that has been leveraged in drug design by 
attaching drugs to glucuronic acid such that they 
will be activated at a site of interest upon hydrolysis 
(15). 
As a by-product of glucuronide hydrolysis, 
bacteria regenerate the original molecule that was 
eliminated by the host, facilitating reuptake by the 
GI epithelia and recirculation in the bloodstream 
(16). Glucuronidation in the liver, delivery to the GI 
lumen via the bile duct, reactivation and absorption 
via the intestinal epithelia, and transport back to the 
liver is termed enterohepatic circulation (Figure 1) 
(17), and it can significantly affect the 
pharmacokinetics of many drugs and also regulates 
the levels of endogenous compounds (4, 17, 18). 
Thus, GI microbial GUS enzymes have the 
capability of directly regulating local and systemic 
levels of exogenous and endogenous compounds 
involved in mammalian homeostasis. 
 
Endogenous Glucuronides in the Gut 
Endogenous glucuronides were clearly the 
driving force for the symbiotic evolution of host-
associated bacterial GUS enzymes. Glucuronidated 
endogenous compounds include bilirubin, 
hormones, neurotransmitters, bile acids, and fatty 
acids, all of which influence host homeostasis. As 
such, GI microbial GUS enzymes participate in a 
nearly constant mutual symbiosis via the regulation 
of local and systemic levels of endogenous 
molecules. 
One the most heavily glucuronidated 
endogenous molecules is bilirubin, a breakdown 
product of heme (19). While it is generally 
considered a waste product and toxin that 
contributes to hyperbilirubinemia and neonatal 
jaundice, normal levels of bilirubin have more 
recently been shown to have preventative 
antioxidant activities (20, 21). Approximately 16% 
and 80% of bilirubin exists as the monoglucuronide 
and diglucuronide conjugates, respectively, in the 
bile of healthy humans (19). Bilirubin glucuronides 
are generated in the liver by UGT1A1 and enter the 
GI tract from the bile duct. In the GI, bilirubin 
glucuronides are heavily metabolized by the 
intestinal microbiota into stercobilin, which gives 
feces its brown color, and urobilin, which is 
responsible for the yellow color of urine and the 
yellow complexion of jaundiced subjects (22). The 
deconjugated bilirubin that manages to escape 
further metabolism by bacteria is reabsorbed 
through the GI epithelia and undergoes 
enterohepatic circulation (18). However, 
enterohepatic circulation of bilirubin in healthy 
humans is relatively low due to bilirubin’s nearly 
complete glucuronidation by the host and 
substantial subsequent metabolism to stercobilin 
and urobilin by the GI microbiota. In certain 
neonates or subjects with Gilbert’s syndrome, 
though, bilirubin is significantly recycled, which 
contributes to CNS-toxic hyperbilirubinemia (19, 
20). Thus, bacterial GUS and human UGT enzymes 
appear to have co-evolved a mutually symbiotic 
heme catabolism pathway to rid the host of high 
levels of toxic bilirubin and to provide the GI 
microbiota with a source of energy in the form of 
glucuronic acid. 
Unconjugated bilirubin is also capable of 
forming insoluble calcium salts that contribute to 
the generation of brown pigment stones in the 
gallbladder and the biliary ductal system, which 
reduce bile flow and can impair liver function (23). 
Interestingly, the generation of these stones is 
concomitant with the presence of GUS-expressing 
Proteobacteria like Escherichia coli and Klebsiella 
pneumoniae, suggesting that bacterial GUS activity 
may promote the formation of the unconjugated 
bilirubin salts found in gall stones (23, 24). Bacteria 
of the family Enterobacteriaceae, which include E. 
coli and K. pneumoniae, are more abundant in the 
bile (25). The low affinity GUS inhibitor glucaro-
1,4-lactone blocked calcium bilirubinate 
precipitation in vitro (23).  
Hormones are also subject to 
glucuronidation. The estrogen metabolites 
estradiol, estrone, and estriol are glucuronidated by 
multiple UGT isoforms (26). In vitro studies have 
shown that E. coli GUS is capable of hydrolyzing a 
glucuronide metabolite of estriol, and does so with 
much greater activity than human GUS (27). 
Furthermore, estrogen metabolites exhibit 
significant enterohepatic circulation, suggesting 
that the regeneration of estrogen aglycones by the 
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GI microbiota may play an important role in 
regulating plasma levels of this hormone (28). 
Radiolabeling studies reveal that enterohepatic 
circulation of estrone and estriol varies by host 
species, which suggests that species differences in 
UGT expression or microbial composition may 
impact hormone metabolism (29). While bacterial 
GUS has been demonstrated in vitro to hydrolyze 
estrogenic glucuronides, a definitive role for the GI 
microbiota in the enterohepatic circulation of 
estrogenic metabolites in vivo has not been 
established. However, as posited recently, the 
reactivation of estrogenic metabolites by the GI 
microbiota may promote the enterohepatic 
circulation of estrogenic metabolites, which may 
subsequently foster the growth of estrogen-
responsive tumors (30).  It is important to note, 
though, that estrogen metabolites are also heavily 
sulfated through the action of mammalian 
sulfotransferases, another set of Phase 2 drug 
metabolizing enzymes that perform a role 
analogous to the glucuronidating UGTs (26). GI 
bacteria also harbor a variety of sulfatases to 
process highly sulfated polysaccharides and 
sulfated small molecules, including estrogen 
metabolites (26, 31). Overall, mammalian hormone 
inactivation is likely closely mirrored, and reversed, 
by enzymes in the GI microbiota. 
Other glucuronidated hormones include the 
androgen testosterone and the thyroid hormone 
thyroxine (32, 33). Both androgen and thyroxine 
glucuronides can be hydrolyzed by bacterial GUS 
enzymes (27, 34, 35). Androgens are key drivers of 
prostate cancer, resulting in therapies primarily 
focused on androgen deprivation in the form of 
surgical or chemical castration, although a more 
recent approach is the enhancement of androgen 
glucuronidation by UGTs (7). Thyroxine is a 
primary thyroid hormone that impacts a variety of 
processes including metabolic regulation (36). In 
vivo radiolabeling and ex vivo fecal assays indicate 
that bacteria play a key role in the enterohepatic 
circulation of thyroxine in mammals (34). As such, 
GI microbial GUS proteins could participate in the 
regulation of metabolism and development by 
promoting the enterohepatic circulation of 
thyroxine. 
The neurotransmitters dopamine, 
norepinephrine, and serotonin are glucuronidated in 
the body and metabolized by bacterial GUS.  
Roughly 50% of all dopamine is generated in the GI 
(37), where it acts as a regulator of GI motility and 
water absorption (38, 39). Microbes were recently 
shown to have a significant role in the processing 
of dopamine glucuronide in the GI lumen of mice 
(5). This study utilized germ-free mouse models 
and GUS knockout strains of bacteria to 
demonstrate that microbial GUS activity is 
primarily responsible for dopamine glucuronide 
hydrolysis. The neurotransmitter norepinephrine, a 
chemical cousin of dopamine, is also 
glucuronidated and exhibited microbe-mediated 
glucuronide hydrolysis in the GI lumen (5). 
Similarly, serotonin is subject to glucuronidation, 
and plasma levels of serotonin in mice fluctuate 
based on the presence or absence of the microbiota 
(40, 41). 
Bile acids are important to gut health and 
are significantly processed by the microbiota. Bile 
acids are primarily considered detergents that 
solubilize dietary components for digestion (42). 
Much like bilirubin, bile acids are heavily 
metabolized by the microbiota, which can 
dehydrate, oxidize, and deconjugate bile acid 
variants generated by the liver (43). In the liver, bile 
acids are conjugated to sulfate, taurine, and glycine 
moieties, all of which can be removed by GI 
microbial sulfatases and bile salt hydrolases. Bile 
acids are also glucuronidated in the liver (44), and 
the resulting conjugates account for between 12-
36% of the bile acids excreted in the urine.  By 
contrast, sulfate, glycine, and taurine conjugates 
make up 50-63%, 1.8-28%, and 4.1-8.3% of 
excreted bile acids in the urine, respectively (45). 
Thus, glucuronidated bile acids likely provide a 
significant energy source to bacteria capable of 
processing such compounds. Unraveling the 
connections between host and microbial bile acid 
metabolism pathways will likely reveal new 
insights into the co-evolution of mammals and 
microbes. 
Fatty acids are another class of biological 
detergents processed by liver UGTs. Fatty acids 
play roles in mammalian biology that range from 
cell signaling to membrane integrity (46). Ex vivo 
and in vitro analyses show that a variety of fatty 
acids can be glucuronidated, including arachidonic 
acid, retinoic acid, prostaglandins, and derivatives 
of linoleic acid (47–49), although further studies are 
needed to determine whether fatty acid 
glucuronides are processed by bacterial GUS 
enzymes. 
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Finally, endogenous polysaccharides are a 
critical source of glucuronides in the gut. 
Chondroitin sulfate and hyaluronic acid are 
glucuronic acid-containing polysaccharides present 
in the GI tract (10). Bacteria express a wealth of 
endo- and exo-glycosidases that work in concert to 
break down complex polysaccharides. Analogous 
to human GUS, which catabolizes extracellular 
matrix polysaccharides in lysosomes, bacterial GI 
GUS enzymes play similar roles with substrates 
like chondroitin sulfate that enter the GI from host 
cells sloughed from the epithelia (50). An excellent 
review of microbial polysaccharide processing 
enzymes in the mammalian GI tract has recently 
been provided (51). 
 
Exogenous Glucuronides in the Gut 
Glucuronides of drugs and other exogenous 
molecules have been a primary focus of research 
because of their potential importance to therapeutic 
efficacy and tolerance. Many drugs exhibit GI and 
liver toxicity that is mediated in part by bacterial 
GUS activity in the gut, resulting in a parasitic 
symbiosis in which bacteria receive sugar from 
drug glucuronides and the host retains toxic 
metabolites. Carcinogens and other dietary 
metabolites are also metabolized in the body via 
glucuronidation and processed by our microbial 
counterparts, providing a link between bacterial 
GUS enzymes and carcinogenesis. Exogenous 
glucuronides that reach the GI are diverse in 
chemical structure, suggesting that a proportional 
breadth of functional diversity may be present in the 
collection of microbial GUS enzymes in the GI.  
The anticancer agent SN-38 is the 
archetype of how metabolism by bacterial GUS can 
lead to drug toxicity. SN-38 is the active form of the 
prodrug irinotecan, which is commonly used to 
treat colorectal and pancreatic cancers (52, 53). SN-
38 is inactivated in the liver by conversion to SN-
38-glucuronide (SN-38-G); in the GI lumen, 
however, microbial GUS enzymes recreate SN-38 
and cause severe GI toxicity in the form of dose-
limiting diarrhea. The authors’ laboratory showed 
that potent, selective, and non-lethal inhibition of 
bacterial GUS enzymes reduces the GI toxicity of 
SN-38 in mice (54–56). This approach may 
improve the efficacy and tolerance of other 
anticancer drugs. Indeed, from a list of 155 
anticancer agents, 24 are known to be 
glucuronidated, and of those that are 
glucuronidated, 21 (89% of 24) cause GI toxicity. 
Two such drugs are the histone deacetylase 
(HDAC) inhibitors belinostat and panobinostat, 
used to treat lymphoma (57, 58). Metabolites of 
lapatinib, a GI toxic drug used to treat hormone 
receptor positive breast cancer, are glucuronidated 
and their reactivation may damage the liver as well 
as the GI tract (59). GI microbial GUS enzymes 
contribute to hepatotoxicity via the enhancement of 
enterohepatic circulation, which leads to repeated 
liver exposure to toxic metabolites (17). Together, 
these examples highlight the role that bacterial 
GUS plays in cancer treatment, efficacy, and 
toxicity. 
Non-steroidal anti-inflammatory drugs 
(NSAIDs), some of the most widely used 
therapeutics in the world, are also glucuronidated. 
NSAIDs inhibit cyclooxygenase enzymes and 
prostaglandin synthesis and contain a carboxylic 
acid group that is readily glucuronidated (60). The 
NSAID diclofenac is conjugated to glucuronic acid 
by UGT2B7 in the liver, delivered to the GI tract 
via the bile duct, and hydrolyzed by bacterial GUS 
enzymes in the GI (61, 62). The regeneration of 
diclofenac causes ulceration of the GI epithelia via 
an unclear mechanism that may involve disruption 
of mitochondrial function (63). Similar to SN-38, 
prevention of diclofenac regeneration by a selective 
bacterial GUS inhibitor reduced GI ulceration in 
mice (61). The GI damage of the NSAIDs 
ketoprofen and indomethacin can also be 
ameliorated by selective inhibition of bacterial 
GUS (62). Interestingly, the GI toxicity caused by 
NSAIDs is primarily localized in mice to the distal 
end of the small intestine, while the damage most 
often associated with irinotecan is located in the 
large intestine (64). It is possible that bacteria that 
thrive in the distal small intestine may have a 
greater capability to hydrolyze NSAID 
glucuronides than microbes in the proximal small 
intestine and colon (64).  
Certain carcinogens are also 
glucuronidated. One of the most potent is the 
alkylating agent methylazoxymethanol (MAM), the 
active metabolite of azoxymethanol (AOM) that is 
used to model carcinogenesis in rodents (65). AOM 
is converted by cytochrome P450 2E1 and UGTs in 
the liver to generate MAM-glucuronide (MAM-G),  
and evidence exists that bacteria in the GI tract 
reactivate MAM-G to MAM and promote colon 
carcinogenesis (66, 67). The low-affinity bacterial 
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GUS inhibitor C-GAL has been shown to reduce 
colon carcinogenesis caused by AOM (68). Other 
carcinogens, like the polyaromatic hydrocarbons 
and heterocyclic aromatic amines, are also 
metabolized by the CYP-to-UGT pathway, and it 
has been suggested that microbes hydrolyze those 
glucuronide metabolites as well (69, 70). 
Interestingly, colon cancer patients exhibit higher 
fecal GUS activities than controls (2). Together, 
these results support the conclusion that the release 
of active carcinogens in the GI tract involves 
microbial GUS enzymes. 
Two widely used lifestyle drugs 
metabolized by host UGTs and bacterial GUSs are 
ethanol and nicotine. While the majority of ingested 
ethanol is converted to acetaldehyde by alcohol 
dehydrogenase, a small fraction of ethanol is 
glucuronidated (71). In humans, ethanol 
glucuronide has been detected in the liver, bile and 
urine (72). Escherichia coli and Clostridum 
sordellii have both been shown to hydrolyze ethyl 
glucuronide in vitro, which may contribute to a 
greater retention of ethanol-derived metabolites in 
the body (73). Detection of ethyl glucuronide in 
hair has been employed as a biomarker to diagnose 
alcohol abuse (74). Nicotine and its metabolites are 
primarily processed in humans by oxidation, but 
they are also glucuronidated (75). Nicotine is 
unique among the aglycones discussed here in that 
it is conjugated to glucuronic acid through a 
nitrogen-linkage, and microbial GUS enzymes 
have been shown to cleave nicotine glucuronide 
(76). The glucuronides of ethanol and nicotine 
highlight the chemical diversity of exogenous 
compounds that serve as substrates for GUS 
proteins of the GI microbiota. 
While not the primary focus of this review, 
a small number of plant polysaccharides that 
contain glucuronic acid are mentioned here. Gum 
Arabic is a plant-derived secretion that is 
predominantly composed of glucuronic-acid 
containing polysaccharides, and is widely utilized 
in the food and drug industry as a stabilizer (10, 77). 
This complex polysaccharide is indigestible to 
animals, but can be fermented by bacteria in the 
colon and is associated with weight loss in humans 
(78). The xylan hemicelluloses, which are 
heteropolymers of various sugars and components 
of the plant cell wall, also contain glucuronic acid 
(10). Like Gum Arabic, xylan polysaccharides are 
indigestible by human enzymes, but can be 
catabolized by GI microbes. Xylan complexity 
appears to require a diverse set of microbial 
xylanases to catabolize them to release smaller, 
glucuronic acid-containing sugars further 
processed by intestinal bacteria (79). 
 
Microbial β-Glucuronidases in the Gut 
Several investigations have detected in 
vitro GUS activity, ex vivo fecal GUS activity, and 
in vivo correlations between GI GUS enzyme 
activity and health. These studies have resulted in 
the identification of bacteria related to Crohn’s 
disease, the discovery of increased GUS activity in 
patients with colorectal cancer and subjects on high 
fat diets, and the mechanistic elucidation of how 
bacterial GUS promotes drug toxicity (1, 2, 9, 55). 
To test the relationship between microbial GUS 
activity and disease, total fecal proteins have been 
extracted and GUS assays conducted (80). This 
approach yields an overall view of the fecal 
microbiota’s GUS activity, but provides little 
granularity about the specific microbial enzymes 
involved. Other approaches involve culturing 
bacteria obtained from human fecal samples, and 
then assessing the GUS activity in these pure 
cultures (6, 81–88). A tabulation of strains analyzed 
in culture-based GUS activity assays reveals that 
bacteria from all the major phyla in the mammalian 
GI microbiota, including Actinobacteria, 
Bacteroidetes, Firmicutes, and Proteobacteria, 
harbor enzymes that process glucuronides (Table 
2). The conservation of GUS across all major GI 
bacterial phyla reinforces the hypothesis that GUS 
proteins may play key roles in chemical dynamics 
across the intestinal epithelium, and serve as a 
competitive growth advantage for bacteria in the 
crowded and unforgiving milieu of the mammalian 
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FIGURE LEGENDS 
 
TABLE 1. Examples of molecules subject to glucuronidation in mammals. 
AOM, azoxymethane 
PhIP, 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
NSAID, non-steroidal anti-inflammatory drug 
TABLE 2. Bacterial strains from the human microbiota that have been shown to exhibit GUS activity in 
culture 
FIGURE 1. Enterohepatic circulation of chemically distinct molecules (denoted as X) is mediated by the 
host and microbiota. Glucuronides (e.g., X-glucuronide) are generated primarily in the liver by UGTs (but 
can also be produced by GI epithelial UGTs) and then delivered by biliary secretion to the GI.  In the 
alimentary canal, glucuronides are either excreted or metabolized by the GI microbiota’s GUS enzymes. 
Reactivated aglycones in the GI (X) can be excreted, or reabsorbed and returned to the liver via the 
enterohepatic cycle. 
 
FIGURE 2. Examples of chemically diverse endogenous and exogenous glucuronides (glucuronic acid 
shown in green) generated by mammalian UGT enzymes and metabolized by GI microbial GUS enzymes. 
MAM, methylazoxymethanol 
PhIP, 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
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TABLES 
TABLE 1 
Examples of molecules subject to glucuronidation in mammals. 
 Aglycone Aglycone’s Effect Disease/health Ref. 
ENDOGENOUS    
Arachidonic acid Signaling molecule Inflammation (48) 
Bilirubin Neurotoxin, antioxidant Gall stones, jaundice (19) 
Chenodeoxycholate Detergent Cholestasis (89) 
Chondroitin sulfate Glycosaminoglycan Cancer (90) 
Dopamine GI motility, water absorption IBD, constipation (5) 
Estradiol Sex hormone Breast cancer (26) 
Hyaluronic acid Glycosaminoglycan Cancer (10) 
Norepinephrine GI motility IBD (5) 
Serotonin GI motility IBD (40) 
Testosterone Sex hormone Prostate cancer (32) 
Thyroxine Thyroid regulation Metabolic disorder (36) 
EXOGENOUS    
AOM Alkylating agent Cancer (66) 
Belinostat HDAC inhibitor GI toxicity (57) 
Benzo[a]pyrene DNA adduct formation Cancer 
 
(70) 
Diclofenac NSAID GI toxicity (62) 
Ethanol Depressant Liver toxicity (91) 
Indomethacin NSAID GI toxicity (64) 
Ketoprofen NSAID GI toxicity (62) 
Nicotine Stimulant Addiction (75) 
Panobinostat HDAC inhibitor GI toxicity (58) 
PhIP Alkylating agent Cancer (69) 
SN-38 Topoisomerase I inhibitor GI toxicity (54) 
 at U
niversity of N
orth Carolina at Chapel H
ill on A
ugust 16, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
14 
 
TABLE 2 
Bacterial strains from the human microbiota that have been shown to exhibit GUS activity in 
culture. 
 Strain Ref. Actinobacteria  
Bif. adolescentis JCM 1275 (87) 
Bif. angulatum NCFB 2237 (86) 
Bif. bifidum NCFB 2454 (86) 
Bif. breve NCFB 2257 (86) 
Bif. longum JCM 1217 (87) 
Bif. pseudolongum NCFB 2244 (86) 
Col. aerofaciens JCM 7790 (87) 
Bacteroidetes  
Bac. capillosus ATCC 29799 (84) 
Bac. fragilis NCFB 2217 (86) 
Bac. ovatus ATCC 8483 (84) 
Bac. thetaiotaomicron (87) 
Bac. uniformis JCM 5828 (87) 
Bac. vulgatus DCNC 23 (86) 
P. johnsonii DSM 18315 (84) 
P. merdae ATCC 43184 (84) 
Firmicutes  
Bry. formatexigens DSM 14469 (84) 
C. bartlettii DSM 16795 (84) 
C. bifermentans NCFB 2189 (86) 
C. butyricum DCNC 19 (86) 
C. clostridioforme JCM 1291 (87) 
C. paraputrificum JCM 1293 (87) 
C. perfringens NCTC 8679 (86) 
Ent. faecalis DCNC 24 (86) 
Ent. faecium DCNC 26 (86) 
Eubacterium L-8 (85) 
F. prausnitzii M21/2 (84) 
L. acidophilus DCNC 1237 (86) 
L. gasseri ADH (88) 
Ros. inulinivorans DSM 16841 (84) 
Rum. gnavus E1 (81) 
Sub. variabile DSM 15176 (84) 
Streptococcus LJ-22 (85) 
Proteobacteria  
E. coli HGU-3 (6) 
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FIGURES 
Figure 1 
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Figure 2 
 at U
niversity of N
orth Carolina at Chapel H
ill on A
ugust 16, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Samuel J. Pellock and Matthew R. Redinbo
Glucuronides in the Gut: Sugar-Driven Symbioses Between Microbe and Host
 published online April 7, 2017J. Biol. Chem. 
  
 10.1074/jbc.R116.767434Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
 at U
niversity of N
orth Carolina at Chapel H
ill on A
ugust 16, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
